EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Respiratory Virus Infections and Pulmonary Impairment After Allogeneic Hematopoietic Cell Transplantation

Guang-Shing Cheng iD, Angela P Campbell iD, Hu Xie iD, Chikara Ogimi iD, Alpana Waghmare iD, Jane Kuypers, W Garrett Nichols, Paul Carpenter iD, Lawrence Corey, Cheryl Callais, Brenda M Sandmaier iD, Terry Stevens-Ayers und 5 weitere

The Journal of Infectious Diseases · 17.01.2026 · 233 (1) · e151-e163

DOI: 10.1093/infdis/jiaf503 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 01.10.2025. Verfasst von Guang-Shing Cheng und 16 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Respiratory Tract Infections, Virus Diseases, Bronchiolitis Obliterans. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: US National Institutes of Health, NHLBI NIH HHS, MedImmune Pediatric.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Respiratory virus infections (RVIs) are common after hematopoietic cell transplantation (HCT), but their effect on pulmonary outcomes, including bronchiolitis obliterans syndrome (BOS), and mortality is poorly defined.

Methods

Prospective cohort study of 471 allogeneic HCT recipients transplanted in the pre-COVID-19 pandemic era in an academic cancer center. Participants were prospectively followed for 1 year with serial handheld spirometry, symptom questionnaires, and multiplex 11-virus PCR. Pulmonary function testing occurred at recommended intervals. Cox proportional hazard and generalized estimating equation models were used to estimate associations between RVI and weekly spirometry with late airflow obstruction (AFO), BOS, and overall mortality.

Results

The 1-year cumulative incidence of at least one RVI was 62%; lower respiratory tract disease (LRTD) occurred in 7.6% of patients. Late AFO developed in 15.6% of patients and BOS in 3.9% of patients. Any symptomatic viral upper respiratory tract infections (URTI) were associated with AFO (adjusted HR [aHR] 1.87, 95% CI 1.11–3.16) and BOS (aHR 2.65, 95% CI 1.02–6.91). Individually, PIV-3 URTIs were associated with AFO (aHR 2.83, 95% CI 1.01–7.97) and RSV URTIs were associated with BOS (aHR 6.32, 95% CI 2.04–19.6). Short-term airflow decline was associated with AFO. Any LRTD (aHR 3.49, 95% CI 2.18–5.57), as well as symptomatic influenza URTI (aHR 2.68, 95% CI 1.52–4.72), were associated with mortality.

Conclusions

RVI after HCT, particularly those caused by RSV, PIV-3, and influenza, increase the risk of pulmonary impairment and mortality. These infections should be targeted for specific anti-viral approaches and intensified monitoring for late onset pulmonary disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationRespiratory Tract InfectionsVirus DiseasesBronchiolitis ObliteransHumansMaleFemaleMiddle AgedProspective StudiesAdultAgedTransplantation, HomologousRespiratory Function TestsIncidence

Stichwörter der Autor:innen

pulmonary impairmentrespiratory virustransplantation

Autor:innen und Institutionen

  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Section of Pulmonary and Critical Care Medicine, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Center for Clinical and Translational Research, Seattle Children's Hospital, Seattle, Washington, USA.
  • Department of Pediatrics,University of Washington, Seattle, Washington, USA.
  • Department of Laboratory Medicine & Pathology, University of Washington, Seattle, Washington, USA.

ORCID-Profile: Guang-Shing Cheng, Angela P Campbell, Hu Xie, Chikara Ogimi, Alpana Waghmare, Paul Carpenter, Brenda M Sandmaier, Keith R Jerome, Wendy M Leisenring, Janet A Englund, Michael Boeckh

Förderung

  • US National Institutes of Health
  • NHLBI NIH HHS
  • MedImmune Pediatric
  • Pediatric Infectious Diseases Society
  • Clinical and Translational Research
  • NCRR NIH HHS
  • NIAID NIH HHS
  • Seattle Children's Center

Zitieren

APA

Cheng, G. S., Campbell, A. P., Xie, H., Ogimi, C., Waghmare, A., Kuypers, J., Nichols, W. G., Carpenter, P., Corey, L., Callais, C., Sandmaier, B. M., Stevens-Ayers, T., Jerome, K. R., Chien, J. W., Leisenring, W. M., Englund, J. A., & Boeckh, M. (2026). Respiratory Virus Infections and Pulmonary Impairment After Allogeneic Hematopoietic Cell Transplantation. The Journal of Infectious Diseases, 233(1), e151-e163. https://doi.org/10.1093/infdis/jiaf503

Vancouver

Cheng GS, Campbell AP, Xie H, Ogimi C, Waghmare A, Kuypers J, et al. Respiratory Virus Infections and Pulmonary Impairment After Allogeneic Hematopoietic Cell Transplantation. The Journal of Infectious Diseases. 2026;233(1):e151-e163. doi:10.1093/infdis/jiaf503

BibTeX
@article{Cheng2026,
  author = {Cheng, Guang-Shing and Campbell, Angela P and Xie, Hu and Ogimi, Chikara and Waghmare, Alpana and Kuypers, Jane and Nichols, W Garrett and Carpenter, Paul and Corey, Lawrence and Callais, Cheryl and Sandmaier, Brenda M and Stevens-Ayers, Terry and Jerome, Keith R and Chien, Jason W and Leisenring, Wendy M and Englund, Janet A and Boeckh, Michael},
  title = {Respiratory Virus Infections and Pulmonary Impairment After Allogeneic Hematopoietic Cell Transplantation},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  volume = {233},
  number = {1},
  pages = {e151--e163},
  doi = {10.1093/infdis/jiaf503}
}
Kostenlos starten →